A18.2 Tuberculous peripheral lymphadenopathy

Name of the Condition

• Tuberculous peripheral lymphadenopathy
• ICD Code: A18.2

Summary

Tuberculous peripheral lymphadenopathy is a form of extrapulmonary tuberculosis where Mycobacterium tuberculosis infects the peripheral lymph nodes. This condition occurs when TB bacteria spread from a primary site, typically the lungs, to lymph nodes outside the chest or abdomen. It most commonly affects cervical (neck) lymph nodes but can involve other peripheral sites, such as axillary (armpit) or inguinal (groin) nodes. The infection may present as painless swelling or progress to form abscesses or fistulas.

Causes

Tuberculous peripheral lymphadenopathy is caused by the dissemination of Mycobacterium tuberculosis from an existing infection, usually pulmonary tuberculosis. The bacteria travel through the lymphatic system to reach peripheral nodes. It may result from reactivation of latent TB or direct spread from adjacent infected tissues. In some cases, it occurs as the primary site of TB infection without obvious lung involvement.

Risk Factors

• Immunocompromised states, such as HIV/AIDS or chronic steroid use.
• History of untreated or inadequately treated tuberculosis.
• Close contact with individuals who have active TB.
• Living in or traveling to regions with high TB prevalence.
• Underlying conditions like diabetes or malnutrition.

Symptoms

• Painless swelling of one or more peripheral lymph nodes, often in the neck.
• Enlarged, firm nodes that may feel rubbery.
• Nodes that become tender or fluctuant as the infection progresses.
• Skin discoloration or breakdown over affected nodes in advanced cases.
• Systemic symptoms of TB, such as fever, night sweats, or weight loss, may occur.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging, and laboratory tests. A physical exam identifies enlarged peripheral lymph nodes. Imaging (e.g., ultrasound) assesses node characteristics. Fine-needle aspiration or excisional biopsy of nodes provides tissue for histopathology, acid-fast bacilli (AFB) staining, and culture. Molecular tests (e.g., PCR) may detect TB DNA. Chest imaging checks for pulmonary TB, and tuberculin skin tests or interferon-gamma release assays (IGRAs) evaluate TB exposure.

Treatment Options

Treatment follows standard TB regimens, typically a 6–9 month course of isoniazid, rifampin, pyrazinamide, and ethambutol (initial phase), followed by isoniazid and rifampin (continuation phase). Drug susceptibility testing guides therapy for resistant strains. Surgical drainage may be needed for abscesses or fistulas. Adjunctive corticosteroids are sometimes used for severe inflammation, but their role is limited.

Prognosis and Follow-Up

With appropriate treatment, most patients recover fully. Response is monitored via clinical improvement and resolution of lymph node swelling. Follow-up includes adherence checks and symptom assessment. Relapse is rare but possible, especially with incomplete treatment. Long-term outcomes depend on immune status and timely intervention.

Complications

• Formation of cold abscesses or fistulas.
• Secondary bacterial infection of nodes.
• Scarring or disfigurement from chronic inflammation.
• Spread to other organs (disseminated TB) in immunocompromised individuals.
• Drug resistance if treatment is incomplete or inappropriate.

Lifestyle & Prevention

• Complete the full TB treatment course to prevent recurrence.
• Practice good hygiene to reduce infection risk.
• Avoid close contact with active TB cases.
• Ensure adequate nutrition and manage underlying conditions (e.g., diabetes).
• Vaccination with BCG may be considered in high-prevalence regions, though its efficacy varies.

When to Seek Professional Help

Seek care if lymph node swelling persists, worsens, or is accompanied by fever, night sweats, or weight loss. Prompt evaluation is critical for immunocompromised individuals or those with a history of TB exposure. Immediate attention is needed for nodes that become painful, red, or drain pus.

Tips for Medical Coders

Code A18.2 is assigned for tuberculous peripheral lymphadenopathy, including cervical, axillary, or inguinal node involvement. Document the specific node location and confirm TB confirmation (e.g., biopsy, culture, or molecular testing). Differentiate from other lymph node conditions (e.g., bacterial adenitis) to ensure accurate coding. Include details on treatment response or complications if relevant to the encounter.